FDA CDER Director Richard Pazdur Resigns Amid Internal Controversies and Criticism Over Voucher Programs

On December 2, 2025, the resignation of Dr. Richard Pazdur, director of the FDA’s Center for Drug Evaluation and Research (CDER), was announced following internal controversies that highlighted significant challenges within the agency. Two key events reportedly influenced his decision to step down: a critical memo authored by Dr. Vinay Prasad and concerns raised over voucher programs by Dr. Marty Makary.

Dr. Prasad’s memo allegedly outlined systemic issues within CDER, focusing on regulatory inefficiencies and decision-making processes that may have impacted drug approvals and public trust in the agency. Separately, Dr. Makary raised questions about the use of priority review vouchers, which are intended to expedite drug reviews but have faced scrutiny regarding their implementation and potential misuse. These developments reportedly contributed to growing tensions within the FDA leadership, culminating in Pazdur’s departure after years of service at the helm of CDER.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: The formatted date is: December 2, 2025

Related posts:

Symptom Relief Reported in Dietary Study, But No Single Diet Change Consistently Helpful Proposed 200 Percent Tariff on Pharmaceutical Imports Could Raise Drug Prices and Disrupt U.S. Supply Chain Researchers Develop Lithium-Ion Garnet and Ionic Liquid Method to Improve Solid-State Supercapacitor Performance Study Explores Link Between Pediatric Nurses’ Self-Efficacy and Compassion in Atraumatic Care

Author

GOAI